IGHE and asthma: Omalizumab is an anti-IgE antibody that binds to free IgE in human plasma or interstitial fluid and reduces sensitivity to allergens.[11] In addition to its antiallergic effects in steroid-refractory asthma, some studies have found that omalizumab can stabilize mast cells and act as an immune-stabilizer in nonallergic diseases.[11] Therefore, omalizumab has been approved for the treatment of chronic urticaria, which is influenced by both allergic and nonallergic mechanisms.